Janux Therapeutics vs Prothena
Janux Therapeutics reported revenue of $10 million in fiscal 2025, about the same as Prothena's $10 million in fiscal 2025. Janux Therapeutics' revenue fell 5.5% in its latest year, and Prothena's fell 92.8%. Janux Therapeutics had an operating margin of -1576.7%, against -2216.4% at Prothena.
Side by side
| Janux Therapeutics | Prothena | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $10M | $10M |
| Revenue growth | −5.5% | −92.8% |
| Revenue growth a year, last 5 years | — | 60.9% |
| Gross margin | — | — |
| Operating margin | −1,576.7% | −2,216.4% |
| Net margin | −1,136.2% | −2,520.6% |
| Free cash flow | −$83M | — |
| Free cash flow margin | −832.8% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 15.3% | 0.1% |
| Last close | $10.29 | $8.40 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $457,063 | bought $7.7 million, sold $135,926 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Janux TherapeuticsProthena
Operating margin
Percent of revenue
Janux TherapeuticsProthena
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Janux TherapeuticsProthena
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Janux Therapeutics and Prothena pages.